Drugs / CD123/CD33 CART
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06420063 | Jul 2024 → Dec 2025 overdue | acute myeloid leukemia | Essen Biotech | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD123/CD33 CART | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06420063 ↗ |
| Modality | Cell therapy | “chimeric antigen receptor T cell immunotherapy (CAR-T)” NCT06420063 ↗ |
| Route | Intravenous | “Subsequently, patients will receive CD33/123 CAR T cells intravenously (IV) over a duration of 10-20 minutes on day 0.” NCT06420063 ↗ |